Epoetin alfa biosimilar - Blau FarmaceuticaAlternative Names: Eritromax; recombinant-human-erythropoetin-alfa - BlauFarmaceutica; rHuEPO - Blau
Latest Information Update: 04 May 2015
At a glance
- Originator Blau Farmaceutica
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 14 May 2012 Launched for Anaemia in Brazil (IV, SC)